Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy
Download .nbib